MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program
September 28 2022 - 8:05AM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial
cell-engineering company focused on providing enabling platform
technologies to advance innovative cell-based research as well as
next-generation cell therapeutic discovery, development and
commercialization, today announces the signing of a strategic
platform license (SPL) with Vertex Pharmaceuticals Incorporated, a
global biotechnology company that invests in scientific innovation
to create transformative medicines for people with serious
diseases.
Under the terms of the agreement, Vertex obtains
non-exclusive clinical and commercial rights to use MaxCyte’s Flow
Electroporation® technology and ExPERT™ platform in the development
of its CRISPR/Cas9-based gene-edited therapy (exa-cel, formerly
known as CTX001™), which entitles MaxCyte to receive platform
licensing fees and program related revenue.
Exa-cel is an investigational ex vivo CRISPR
gene-edited cell therapy under evaluation for patients suffering
from transfusion-dependent beta thalassemia (TDT) or sickle cell
disease (SCD) characterized by recurrent vaso-occlusive crises.
The same MaxCyte technology was used in the
development of exa-cel under an agreement between MaxCyte and
CRISPR Therapeutics.
About MaxCyte
MaxCyte is a leading commercial cell-engineering
company focused on providing enabling platform technologies to
advance innovative cell-based research as well as next-generation
cell therapeutic discovery, development and commercialization. Over
the past 20 years, we have developed and commercialized our
proprietary Flow Electroporation® platform, which facilitates
complex engineering of a wide variety of cells. Our ExPERT™
platform, which is based on our Flow Electroporation technology,
has been designed to support the rapidly expanding cell therapy
market and can be utilized across the continuum of the high-growth
cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™ GTx™and VLx™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
About Vertex
Pharmaceuticals
Vertex is a global biotechnology company that
invests in scientific innovation to create transformative medicines
for people with serious diseases. The company has multiple approved
medicines that treat the underlying cause of cystic fibrosis (CF) —
a rare, life-threatening genetic disease — and has several ongoing
clinical and research programs in CF. Beyond CF, Vertex has a
robust pipeline of investigational small molecule medicines in
other serious diseases where it has deep insight into causal human
biology, including pain, alpha-1 antitrypsin deficiency and
APOL1-mediated kidney disease. In addition, Vertex has a rapidly
expanding pipeline of cell and genetic therapies for diseases such
as sickle cell disease, beta thalassemia, Duchenne muscular
dystrophy and type 1 diabetes mellitus.
Founded in 1989 in Cambridge, Mass., Vertex's
global headquarters is now located in Boston's Innovation District
and its international headquarters is in London. Additionally, the
company has research and development sites and commercial offices
in North America, Europe, Australia and Latin America. Vertex is
consistently recognized as one of the industry's top places to
work, including 12 consecutive years on Science magazine's Top
Employers list, one of the 2021 Seramount (formerly Working Mother
Media) 100 Best Companies, and a best place to work for LGBTQ
equality by the Human Rights Campaign.
MaxCyte Contacts:
US IR
AdviserGilmartin GroupDavid Deuchler,
CFA |
+1 415-937-5400
ir@maxcyte.com |
US Media
Relations Valerie Enes Seismic |
+1
408-497-8568 valerie@teamseismic.com |
|
|
Nominated Adviser and
Joint Corporate BrokerPanmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden |
+44 (0)20 7886 2500 |
UK IR
AdviserConsilium Strategic
CommunicationsMary-Jane ElliottChris Welsh |
+44 (0)203 709
5700maxcyte@consilium-comms.com |
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024